Skip to Main Content

SAN FRANCISCO — Verily was one of the most-talked-about debutants at this year’s J.P. Morgan ball. For the first time in its five-year history, the Alphabet life sciences spinout presented to some of the 9,000 health care executives and investors who descended upon Union Square, and Verily’s mercurial CEO, Andy Conrad, faced pressure both to impress and entertain.

The conference room was standing room only on Monday as an enthusiastic Conrad, clad in the Silicon Valley uniform of pullover sweater and open-collar shirt, described some of the company’s numerous projects, teasing details that he said he’d never before shared with the public.


One of those projects was a partnership with diabetes device company Dexcom to make a first-of-its-kind glucose monitor. It seemed to go well. Conrad even engendered a couple of laughs from the audience — a rare JPM treat — while describing how the work has led to insights around the powerful link between calorie-laden fast food and blood sugar spikes.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!